Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Buy" by Analysts

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has been given an average rating of "Buy" by the ten ratings firms that are presently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $23.83.

A number of research firms have weighed in on BNTC. HC Wainwright reiterated a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a research note on Monday, May 19th. TD Cowen started coverage on Benitec Biopharma in a research note on Monday, July 7th. They set a "buy" rating for the company. Finally, JMP Securities restated a "market outperform" rating and set a $20.00 target price on shares of Benitec Biopharma in a research report on Thursday, May 15th.

Institutional Investors Weigh In On Benitec Biopharma

Hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. boosted its holdings in Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after purchasing an additional 20,597 shares in the last quarter. 683 Capital Management LLC purchased a new stake in Benitec Biopharma in the 4th quarter valued at approximately $452,000. Northern Trust Corp boosted its holdings in Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after purchasing an additional 13,425 shares in the last quarter. Informed Momentum Co LLC purchased a new stake in Benitec Biopharma in the 1st quarter valued at approximately $512,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Benitec Biopharma in the 1st quarter valued at approximately $597,000. Institutional investors and hedge funds own 52.19% of the company's stock.

Benitec Biopharma Stock Down 0.1%

Benitec Biopharma stock opened at $11.74 on Friday. The business has a fifty day moving average of $14.06 and a two-hundred day moving average of $12.99. The company has a quick ratio of 14.80, a current ratio of 14.80 and a debt-to-equity ratio of 0.01. The firm has a market cap of $308.18 million, a P/E ratio of -7.77 and a beta of 0.37. Benitec Biopharma has a twelve month low of $7.05 and a twelve month high of $17.15.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.12. On average, analysts forecast that Benitec Biopharma will post -1.48 earnings per share for the current fiscal year.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.